Crossmark

Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells

Crossref DOI link: https://doi.org/10.1186/s12886-018-0978-9

Published Online: 2018-12-11

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Merz, Patrick R. http://orcid.org/0000-0003-2971-0308
Röckel, Nina

Ballikaya, Seda

Auffarth, Gerd U.

Schmack, Ingo
Funding

Funding for this research was provided by:

Novartis Pharma
License Information

Text and Data Mining valid from 2018-12-01
More Information

Article History

Received: 28 June 2018

Accepted: 27 November 2018

First Online: 11 December 2018

Ethics approval and consent to participate

: The study was approved by the Ethikkommission Heidelberg, Germany under the reference number S-318 / 2012. Informed consent was obtained for each donor prior to participation in the study. All procedures conformed to HIPAA regulations and the Declaration of Helsinki for research involving human subjects.

: Not applicable.

: GUA received research grants from Novartis Pharma GmbH. The other authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.